Crinetics Pharmaceuticals’ (NASDAQ:CRNX) lock-up period will end on Monday, January 14th. Crinetics Pharmaceuticals had issued 6,000,000 shares in its IPO on July 18th. The total size of the offering was $102,000,000 based on an initial share price of $17.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

CRNX has been the topic of a number of analyst reports. Zacks Investment Research raised Crinetics Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, November 6th. JPMorgan Chase & Co. decreased their price objective on Crinetics Pharmaceuticals from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 14th.

CRNX opened at $23.37 on Friday. Crinetics Pharmaceuticals has a 52 week low of $19.23 and a 52 week high of $42.00.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last posted its quarterly earnings data on Tuesday, November 13th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.04). The company had revenue of $0.55 million for the quarter, compared to analyst estimates of $0.28 million. Crinetics Pharmaceuticals had a negative net margin of 972.23% and a negative return on equity of 78.81%. Analysts anticipate that Crinetics Pharmaceuticals will post -2.2 earnings per share for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of CRNX. Vivo Capital LLC purchased a new position in Crinetics Pharmaceuticals during the third quarter worth about $108,646,000. FMR LLC purchased a new position in Crinetics Pharmaceuticals during the third quarter worth about $77,866,000. Perceptive Advisors LLC purchased a new position in Crinetics Pharmaceuticals during the third quarter worth about $74,144,000. Janus Henderson Group PLC purchased a new position in Crinetics Pharmaceuticals during the third quarter worth about $15,034,000. Finally, BlackRock Inc. purchased a new position in Crinetics Pharmaceuticals during the third quarter worth about $12,013,000. 67.26% of the stock is currently owned by institutional investors and hedge funds.

WARNING: This report was first reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2019/01/12/crinetics-pharmaceuticals-incs-crnx-lock-up-period-to-expire-tomorrow.html.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly.

Recommended Story: Why is the LIBOR significant?

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.